Prelude Therapeutics Incorporated (PRLD) financial statements and ratios from SEC XBRL: revenue $12.14M (TTM), net margin -819.6%, revenue growth 73.4% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $12.14M |
| Net Margin | -819.6% |
| Revenue Growth (YoY) | 73.4% |
| EPS Growth (YoY) | -23.2% |
| FCF Growth (YoY) | -45.6% |
| Price / Book | 3.95 |
| Price / Sales | 24.73 |
| FCF Yield | -30.3% |
| Altman Z-Score | -5.23 (distress) |
| Sector P/E (Healthcare) | 21.7 |
PRLD overview · PRLD earnings · PRLD KPIs · PRLD investor relations · PRLD ownership · PRLD peers · PRLD filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.